Evotec SE (NASDAQ:EVO - Free Report) - Research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Evotec in a report issued on Thursday, April 25th. HC Wainwright analyst D. Tsao expects that the company will earn ($0.03) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Evotec's Q2 2024 earnings at ($0.04) EPS, Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at $0.00 EPS and FY2028 earnings at $0.45 EPS.
EVO has been the subject of a number of other research reports. Royal Bank of Canada upgraded Evotec from a "sector perform" rating to an "outperform" rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "hold" rating to a "buy" rating in a research note on Friday, April 12th.
View Our Latest Stock Report on Evotec
Evotec Trading Down 1.6 %
EVO stock traded down $0.08 during trading on Friday, reaching $5.02. The company's stock had a trading volume of 869,112 shares, compared to its average volume of 106,520. Evotec has a 1 year low of $4.87 and a 1 year high of $13.49. The company's fifty day moving average is $7.29 and its 200-day moving average is $8.65.
Institutional Investors Weigh In On Evotec
Large investors have recently made changes to their positions in the company. Quadrant Capital Group LLC purchased a new position in Evotec during the 4th quarter valued at approximately $25,000. Optiver Holding B.V. increased its stake in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock worth $945,000 after acquiring an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in Evotec in the 4th quarter worth approximately $53,931,000. 5.81% of the stock is owned by institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
